GlassScriptPhysician profile
Stacea N Bowen
NPI 1215115852
$3,773.60
in general payments reported to CMS, 2019-2025
31 companies · $498 in 2025
The $498 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $130 · 2021: $483 · 2022: $517 · 2023: $739 · 2024: $447 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.16 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $679.52 | 2021-2025 | |
| Abbvie INC. | $462.45 | 2019-2023 | Orilissa, Lo Loestrin Fe, Botox |
| Astellas Pharma US INC | $433.12 | 2019-2025 | Veozah, Myrbetriq |
| Kvk-Tech, INC. | $356.68 | 2019-2020 | |
| Novo Nordisk INC | $205.75 | 2019-2023 | Wegovy, Saxenda |
| Lupin INC. | $189.28 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $184.50 | 2023-2025 | Myfembree |
| Agile Therapeutics, INC. | $164.35 | 2021-2024 | Twirla |
| Allergan, INC. | $161.61 | 2019 | |
| Hologic Sales and Service, LLC | $135.19 | 2021-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Myovant Sciences INC. | $116.73 | 2022 | |
| Biogen, INC. | $75.20 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $74.05 | 2019-2023 | |
| Exeltis, USA INC. | $66.55 | 2019-2023 | Slynd |
| Pfizer INC. | $64.94 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $56.11 | 2023 | Cologuard Collection Kit |
| Covidien LP | $49.99 | 2019 | |
| Idorsia Pharmaceuticals US INC | $43.32 | 2023 | Quviviq |
| Lilly USA, LLC | $36.65 | 2024-2025 | Zepbound |
| Therapeuticsmd, INC. | $29.00 | 2022 | |
| Shield Therapeutics INC | $24.60 | 2022 | |
| Intuitive Surgical, INC. | $22.75 | 2020 | |
| Organon LLC | $21.94 | 2024 | |
| Daiichi Sankyo INC. | $18.12 | 2019 | |
| Boston Scientific Corporation | $16.67 | 2021 | |
| Baxter Healthcare | $16.48 | 2025 | Perclot |
| Radius Health, INC. | $16.41 | 2019 | |
| Tactile Systems Technology INC | $14.07 | 2020 | |
| Avion Pharmaceuticals | $13.08 | 2021 | |
| Vivus LLC | $12.97 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacea Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.